Ann Hynes
Stock Analyst at Mizuho
(4.39)
# 345
Out of 5,090 analysts
271
Total ratings
64.04%
Success rate
12.34%
Average return
Main Sectors:
Stocks Rated by Ann Hynes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDT Ardent Health | Maintains: Outperform | $20 → $13 | $8.81 | +47.56% | 3 | Nov 18, 2025 | |
| SGRY Surgery Partners | Maintains: Outperform | $28 → $22 | $17.07 | +28.88% | 3 | Nov 17, 2025 | |
| ELV Elevance Health | Maintains: Outperform | $420 → $400 | $329.54 | +21.38% | 6 | Nov 4, 2025 | |
| HCA HCA Healthcare | Maintains: Outperform | $475 → $505 | $486.84 | +3.73% | 22 | Oct 27, 2025 | |
| MEDP Medpace Holdings | Maintains: Outperform | $575 → $655 | $546.61 | +19.83% | 5 | Oct 24, 2025 | |
| THC Tenet Healthcare | Maintains: Outperform | $194 → $225 | $211.95 | +6.16% | 16 | Oct 17, 2025 | |
| DGX Quest Diagnostics | Maintains: Outperform | $190 → $210 | $182.96 | +14.78% | 16 | Oct 17, 2025 | |
| LH Labcorp Holdings | Maintains: Outperform | $285 → $320 | $258.99 | +23.56% | 16 | Oct 17, 2025 | |
| FTRE Fortrea Holdings | Maintains: Neutral | $7 → $9 | $14.56 | -38.19% | 5 | Oct 17, 2025 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $155 → $174 | $185.18 | -6.04% | 3 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $32 | $35.91 | -10.89% | 2 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $430 | $330.86 | +29.96% | 21 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $345 | $257.43 | +34.02% | 9 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $28 → $40 | $38.09 | +5.01% | 9 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $88 | $75.34 | +16.80% | 11 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $32 → $22 | $14.63 | +50.38% | 12 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $190 → $225 | $224.72 | +0.12% | 13 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $173 → $225 | $187.96 | +19.71% | 16 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $400 → $330 | $150.38 | +119.44% | 9 | Jul 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $15 | $22.10 | -32.13% | 11 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $110 → $120 | $198.89 | -39.67% | 8 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $19.37 | +44.59% | 1 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $93 → $95 | $112.67 | -15.68% | 8 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $370 → $385 | $265.22 | +45.16% | 10 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $175 → $200 | $230.74 | -13.32% | 15 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $242 → $268 | $2.07 | +12,878.21% | 1 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $450 → $505 | $810.54 | -37.70% | 19 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $57 | $1.34 | +4,145.81% | 1 | Sep 21, 2017 |
Ardent Health
Nov 18, 2025
Maintains: Outperform
Price Target: $20 → $13
Current: $8.81
Upside: +47.56%
Surgery Partners
Nov 17, 2025
Maintains: Outperform
Price Target: $28 → $22
Current: $17.07
Upside: +28.88%
Elevance Health
Nov 4, 2025
Maintains: Outperform
Price Target: $420 → $400
Current: $329.54
Upside: +21.38%
HCA Healthcare
Oct 27, 2025
Maintains: Outperform
Price Target: $475 → $505
Current: $486.84
Upside: +3.73%
Medpace Holdings
Oct 24, 2025
Maintains: Outperform
Price Target: $575 → $655
Current: $546.61
Upside: +19.83%
Tenet Healthcare
Oct 17, 2025
Maintains: Outperform
Price Target: $194 → $225
Current: $211.95
Upside: +6.16%
Quest Diagnostics
Oct 17, 2025
Maintains: Outperform
Price Target: $190 → $210
Current: $182.96
Upside: +14.78%
Labcorp Holdings
Oct 17, 2025
Maintains: Outperform
Price Target: $285 → $320
Current: $258.99
Upside: +23.56%
Fortrea Holdings
Oct 17, 2025
Maintains: Neutral
Price Target: $7 → $9
Current: $14.56
Upside: -38.19%
Charles River Laboratories International
Oct 17, 2025
Maintains: Neutral
Price Target: $155 → $174
Current: $185.18
Upside: -6.04%
Oct 17, 2025
Maintains: Outperform
Price Target: $26 → $32
Current: $35.91
Upside: -10.89%
Oct 9, 2025
Maintains: Outperform
Price Target: $300 → $430
Current: $330.86
Upside: +29.96%
Oct 9, 2025
Maintains: Outperform
Price Target: $300 → $345
Current: $257.43
Upside: +34.02%
Oct 9, 2025
Maintains: Neutral
Price Target: $28 → $40
Current: $38.09
Upside: +5.01%
Oct 9, 2025
Maintains: Outperform
Price Target: $76 → $88
Current: $75.34
Upside: +16.80%
Aug 14, 2025
Maintains: Neutral
Price Target: $32 → $22
Current: $14.63
Upside: +50.38%
Jul 25, 2025
Maintains: Outperform
Price Target: $190 → $225
Current: $224.72
Upside: +0.12%
Jul 25, 2025
Maintains: Outperform
Price Target: $173 → $225
Current: $187.96
Upside: +19.71%
Jul 11, 2025
Maintains: Outperform
Price Target: $400 → $330
Current: $150.38
Upside: +119.44%
Nov 19, 2024
Maintains: Neutral
Price Target: $13 → $15
Current: $22.10
Upside: -32.13%
Nov 4, 2024
Maintains: Neutral
Price Target: $110 → $120
Current: $198.89
Upside: -39.67%
Aug 19, 2024
Initiates: Outperform
Price Target: $28
Current: $19.37
Upside: +44.59%
Apr 25, 2024
Maintains: Buy
Price Target: $93 → $95
Current: $112.67
Upside: -15.68%
Mar 8, 2024
Maintains: Buy
Price Target: $370 → $385
Current: $265.22
Upside: +45.16%
Mar 6, 2024
Maintains: Buy
Price Target: $175 → $200
Current: $230.74
Upside: -13.32%
Feb 23, 2024
Maintains: Buy
Price Target: $242 → $268
Current: $2.07
Upside: +12,878.21%
Feb 9, 2024
Maintains: Neutral
Price Target: $450 → $505
Current: $810.54
Upside: -37.70%
Sep 21, 2017
Initiates: Neutral
Price Target: $57
Current: $1.34
Upside: +4,145.81%